Cargando…
Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis
Mesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute graft-versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT). DSCs are more im...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504152/ https://www.ncbi.nlm.nih.gov/pubmed/28744284 http://dx.doi.org/10.3389/fimmu.2017.00795 |
_version_ | 1783249227643617280 |
---|---|
author | Baygan, Arjang Aronsson-Kurttila, Wictor Moretti, Gianluca Tibert, Babylonia Dahllöf, Göran Klingspor, Lena Gustafsson, Britt Khoein, Bita Moll, Guido Hausmann, Charlotta Svahn, Britt-Marie Westgren, Magnus Remberger, Mats Sadeghi, Behnam Ringden, Olle |
author_facet | Baygan, Arjang Aronsson-Kurttila, Wictor Moretti, Gianluca Tibert, Babylonia Dahllöf, Göran Klingspor, Lena Gustafsson, Britt Khoein, Bita Moll, Guido Hausmann, Charlotta Svahn, Britt-Marie Westgren, Magnus Remberger, Mats Sadeghi, Behnam Ringden, Olle |
author_sort | Baygan, Arjang |
collection | PubMed |
description | Mesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute graft-versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT). DSCs are more immunosuppressive than MSCs. We assessed adverse events and safety using DSCs among 44 treated patients and 40 controls. The median dose of infused cells was 1.5 (range 0.9–2.9) × 10(6) DSCs/kg. The patients were given 2 (1–5) doses, with a total of 82 infusions. Monitoring ended 3 months after the last DSC infusion. Three patients had transient reactions during DSC infusion. Laboratory values, hemorrhages, and transfusions were similar in the two groups. The frequency of leukemic relapse (2/2, DSC/controls) and invasive fungal infections (6/6) were the same in the two groups. Causes of death were those seen in HSCT patients: infections (5/3), respiratory failure (1/1), circulatory failure (3/1), thromboembolism (1/0), multiorgan failure (0/1), and GVHD and others (2/7). One-year survival for the DSC patients with GVHD was 67%, which was significantly better than achieved previously at our center. One-year survival was 90% in the DSC-treated HC group. DSC infusions appear safe. Randomized studies are required to prove efficacy. |
format | Online Article Text |
id | pubmed-5504152 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55041522017-07-25 Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis Baygan, Arjang Aronsson-Kurttila, Wictor Moretti, Gianluca Tibert, Babylonia Dahllöf, Göran Klingspor, Lena Gustafsson, Britt Khoein, Bita Moll, Guido Hausmann, Charlotta Svahn, Britt-Marie Westgren, Magnus Remberger, Mats Sadeghi, Behnam Ringden, Olle Front Immunol Immunology Mesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute graft-versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT). DSCs are more immunosuppressive than MSCs. We assessed adverse events and safety using DSCs among 44 treated patients and 40 controls. The median dose of infused cells was 1.5 (range 0.9–2.9) × 10(6) DSCs/kg. The patients were given 2 (1–5) doses, with a total of 82 infusions. Monitoring ended 3 months after the last DSC infusion. Three patients had transient reactions during DSC infusion. Laboratory values, hemorrhages, and transfusions were similar in the two groups. The frequency of leukemic relapse (2/2, DSC/controls) and invasive fungal infections (6/6) were the same in the two groups. Causes of death were those seen in HSCT patients: infections (5/3), respiratory failure (1/1), circulatory failure (3/1), thromboembolism (1/0), multiorgan failure (0/1), and GVHD and others (2/7). One-year survival for the DSC patients with GVHD was 67%, which was significantly better than achieved previously at our center. One-year survival was 90% in the DSC-treated HC group. DSC infusions appear safe. Randomized studies are required to prove efficacy. Frontiers Media S.A. 2017-07-11 /pmc/articles/PMC5504152/ /pubmed/28744284 http://dx.doi.org/10.3389/fimmu.2017.00795 Text en Copyright © 2017 Baygan, Aronsson-Kurttila, Moretti, Tibert, Dahllöf, Klingspor, Gustafsson, Khoein, Moll, Hausmann, Svahn, Westgren, Remberger, Sadeghi and Ringden. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Baygan, Arjang Aronsson-Kurttila, Wictor Moretti, Gianluca Tibert, Babylonia Dahllöf, Göran Klingspor, Lena Gustafsson, Britt Khoein, Bita Moll, Guido Hausmann, Charlotta Svahn, Britt-Marie Westgren, Magnus Remberger, Mats Sadeghi, Behnam Ringden, Olle Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis |
title | Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis |
title_full | Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis |
title_fullStr | Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis |
title_full_unstemmed | Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis |
title_short | Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis |
title_sort | safety and side effects of using placenta-derived decidual stromal cells for graft-versus-host disease and hemorrhagic cystitis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504152/ https://www.ncbi.nlm.nih.gov/pubmed/28744284 http://dx.doi.org/10.3389/fimmu.2017.00795 |
work_keys_str_mv | AT bayganarjang safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT aronssonkurttilawictor safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT morettigianluca safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT tibertbabylonia safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT dahllofgoran safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT klingsporlena safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT gustafssonbritt safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT khoeinbita safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT mollguido safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT hausmanncharlotta safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT svahnbrittmarie safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT westgrenmagnus safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT rembergermats safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT sadeghibehnam safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis AT ringdenolle safetyandsideeffectsofusingplacentaderiveddecidualstromalcellsforgraftversushostdiseaseandhemorrhagiccystitis |